These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38162440)

  • 21. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.
    Magro G
    Mult Scler Relat Disord; 2022 Sep; 65():104037. PubMed ID: 35835028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
    Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
    Yamamura T; Weinshenker B; Yeaman MR; De Seze J; Patti F; Lobo P; von Büdingen HC; Kou X; Weber K; Greenberg B
    Mult Scler Relat Disord; 2022 Oct; 66():104025. PubMed ID: 36007339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
    Illés Z
    Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Satralizumab: First Approval.
    Heo YA
    Drugs; 2020 Sep; 80(14):1477-1482. PubMed ID: 32797372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What's new in neuromyelitis optica spectrum disorder treatment?
    Chu YC; Huang TL
    Taiwan J Ophthalmol; 2022; 12(3):249-263. PubMed ID: 36248092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder.
    Magro G
    Clin Immunol; 2022 Aug; 241():109072. PubMed ID: 35798242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
    Rosso M; Saxena S; Chitnis T
    Expert Rev Neurother; 2020 May; 20(5):509-516. PubMed ID: 32306778
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    Holmøy T; Høglund RA; Illes Z; Myhr KM; Torkildsen Ø
    J Neurol; 2021 Dec; 268(12):4522-4536. PubMed ID: 33011853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy.
    Munger KC; Samkoff LM
    Mult Scler Relat Disord; 2020 Jan; 37():101442. PubMed ID: 32173005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives.
    Ssemmanda S; Musubire AK
    BMC Neurol; 2023 Sep; 23(1):315. PubMed ID: 37667215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.
    Hoffmann F; Kraft A; Heigl F; Mauch E; Koehler J; Harms L; Kümpfel T; Köhler W; Ehrlich S; Bayas A; Weinmann-Menke J; Beuker C; Henn KH; Ayzenberg I; Ellrichmann G; Hellwig K; Klingel R; Fassbender CM; Fritz H; Slowinski T; Weihprecht H; Brand M; Stiegler T; Galle J; Schimrigk S
    Ther Adv Neurol Disord; 2018; 11():1756286418774973. PubMed ID: 29872456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromyelitis Optica Spectrum Disorder: A Rare Case of Transverse Myelitis and Autonomic Dysfunction.
    Bugshan TF; Asiri M; Alqahtani M; Maghrabi R; Alotaibi HS; Alharbi N
    Cureus; 2023 May; 15(5):e38791. PubMed ID: 37303442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent optic neuritis in a patient with Sjogren syndrome and neuromyelitis optica spectrum disorder: A case report.
    Zheng W; Liu X; Hou X; Zhu Y; Zhang T; Liao L
    Medicine (Baltimore); 2020 Nov; 99(45):e23029. PubMed ID: 33157952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.